...
首页> 外文期刊>International journal of hematology >Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia
【24h】

Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia

机译:成人急性髓性白血病中与最小残留疾病(MRD)检测相关的髓样抑制细胞(MDSC)的增加

获取原文
获取原文并翻译 | 示例

摘要

Myeloid-derived suppressor cells (MDSCs) are thought to help provide a cellular microenvironments in many solid tumors, in which transformed cells proliferate, acquire new mutations, and evade host immunosurveillance. In the present study, we found that MDSCs (CD33 + CD11b + HLA-DRloweg) in bone marrow were significantly increased in adult acute myeloid leukemia (AML) patients. MDSCs levels in newly diagnosed AML patients correlated well with extramedullary infiltration and plasma D-dimer levels. Remission rates in the MDSCs > 1500 group and MDSCs < 1500 group were 72.73 and 81.25 %, respectively. No significant differences were found between the two groups. MDSC levels in the complete remission group were significantly decreased after chemotherapy, while in the partial remission and non-remission groups, there were no significant differences. The level of MDSCs in the high minimal residual disease (MRD) group was significantly higher than that in the middle and low MRD groups. High levels of Wilms' Tumor-1 (WT-1) protein were strongly correlated with higher bone marrow MDSC levels. In conclusion, we report here a population of immunosuppressive monocytes in the bone marrow of patients with AML characterized by the CD33(high)CD11b + HLA-DRloweg phenotype. These cells appear to impact the clinical course and prognosis of AML. This data may provide potentially important targets for novel therapies.
机译:骨髓来源的抑制细胞(MDSC)被认为有助于在许多实体瘤中提供细胞微环境,其中转化的细胞增殖,获得新的突变并逃避宿主的免疫监视。在本研究中,我们发现成人急性髓细胞白血病(AML)患者的骨髓MDSCs(CD33 + CD11b + HLA-DRlow / neg)显着增加。新诊断的AML患者的MDSCs水平与髓外浸润和血浆D-二聚体水平密切相关。 MDSC> 1500组和MDSC <1500组的缓解率分别为72.73和81.25%。两组之间没有发现显着差异。完全缓解组的MDSC水平在化疗后显着降低,而部分缓解组和非缓解组的MDSC水平没有显着差异。高最小残留病(MRD)组的MDSCs水平显着高于中低MRD组的MDSCs水平。高水平的维尔姆斯肿瘤-1(WT-1)蛋白与较高的骨髓MDSC水平密切相关。总之,我们在此报告了以CD33(high)CD11b + HLA-DRlow / neg表型为特征的AML患者骨髓中的免疫抑制单核细胞群体。这些细胞似乎会影响AML的临床进程和预后。该数据可能为新型疗法提供潜在的重要靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号